Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Prospect Research Manager

  • Chelsea
  • Development and Communications Directorate
  • £41,600 - £43,000
  • Permanent

About the Role Our Prospect Research team plays a central role in unlocking new funding opportunities across the ICR's philanthropic income streams. It is responsible for delivering high quality, insightful prospect briefings and fundraising intelligence, which supports the ICR's fundraisers in their efforts to build meaningful relationships with philanthropic high net-worth individuals, trusts, foundations and corporates who have the interest and capacity to support the ICR's vital research. The post holder will play a key role in supporting the Development & Communications directorate to source, assess and validate new funding opportunities, maximise income secured across our philanthropic income streams and fundraising campaign, and grow our incredible donor community. The successful candidate will have experience of devising and successfully implementing targeted prospecting strategies. You will play a lead role in identifying philanthropic HNWIs and corporates with the capacity and inclination to support our work. The post holder will also be responsible for carrying out due diligence research and alerting fundraisers to reputational risks identified in support of the ICR's gift acceptance policy. You will work closely with the Head of Prospect Development to support fundraisers in maximising the success of our senior volunteer network through network mapping and expanding its ranks. In addition, the post holder will manage the Prospect Research Executive, providing development and mentoring support. What We Offer A supportive and collaborative working environment. Opportunities for professional development and career progression. Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Caroline Porter via telephone on 020 7153 5486 or email at [email protected].

Higher Scientific Officer (bioinformatician)

  • Sutton
  • Systems and Precision Cancer Medicine
  • £39,805 - £49,023 per annum
  • Fixed term

Under the guidance of Prof Anguraj Sadanandam, we are seeking to recruit a Bioinformatician (Senior Scientific Officer) to contribute to implementing and performing relevant analyses, interpreting the results in context of fast-moving projects, and presenting the results to project teams as well as internal and external collaborators and contribute, with the expectation of authorship on resulting publications. There will also be opportunities to engage in bench-based experimental research, although this is not mandatory. The successful candidate will play a key role in analysing RNAseq data (bulk, single-cell, spatial), developing methodologies and supporting research activities. About you The successful candidate must have: Master’s degree in Computational Biology, Bioinformatics, Computer Science, or related subject Proven experience of bioinformatics analyses and interpretation in one or more of the following key areas (NGS analysis of WES/WGS/RNAseq (bulk, single-cell) using standard practice pipelines; Clinical data analysis (Survival curves, correlation and subgroup analysis) Proven experience in the development of software pipelines to implement analysis workflow Proven experience in use of High Performance Computing platforms and unix-like operating systems Proven experience of writing and maintaining Python, R and Bash code using Git Department/Directorate Information The Division of Molecular Pathology conducts translational research linking molecular science to clinical oncology. The group of Dr Anguraj Sadanandam focuses on cancer metabolism and tumour subtypes, particularly in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Using integrative multi-omics approaches — including scRNAseq, spatial transcriptomics, bulk RNAseq, metabolomics (LC-MS), CNV, and WES — combined with cell culture and genetically engineered mouse models, we aim to define tumour heterogeneity and identify new therapeutic opportunities. The successful candidate will work under multidisciplinary supervision: for clinical and biological questions, guidance will be provided by Dr Christophe Cisarovsky, Clinical Oncologist in the GI clinic at The Royal Marsden Hospital and MD-PhD, together with Group Leader Prof Anguraj Sadanandam; for technical and bioinformatics questions, supervision will be provided by Prof Anguraj Sadanandam and members of his bioinformatics team. The candidate will primarily perform bioinformatic analyses and contribute to fast-moving projects with the expectation of authorship on resulting publications. There will also be opportunities to engage in bench-based experimental research, although this is not mandatory. https://www.icr.ac.uk/research-and-discoveries/find-a-researcher/test-researcher-profile-detail/dr-anguraj-sadanandam What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Christophe Cisarovsky via Email on [email protected].

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

10/09/25

Scientists have developed a new test that can decode when someone’s cancer first started growing and how fast it is growing, potentially allowing doctors to accurately predict when a patient will need treatment.
Man working out at the gym. Puregym, ICR and Royal Marsden logo in the background

06/09/25

The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have teamed up with Sir Chris Hoy and PureGym to launch a collaboration to encourage men with prostate cancer to be more active.
Dr Joerg Mansfeld

27/08/25

Researchers have discovered a tiny chemical switch inside our cells that helps control whether they keep dividing or stop for good – a finding that could influence future cancer therapies and deepen our understanding of ageing.
Tubulin (green) and DAPI (magenta) staining in H2228 lung cancer cells

21/08/25

Seven images were shortlisted for this year’s annual Science and Medical Image competition, showcasing the eye-catching science being carried out at the ICR. Three winners were selected by a judging panel and the fourth was chosen by the public based on votes on social media.